Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :29416702
Publication Date : //

Drug resistance related to aberrant glycosylation in colorectal cancer.


Colorectal cancer (CRC) is the fourth leading cause of cancer-related deaths in the world. Drug resistance of tumour cells remains the main challenge toward curative treatments efficiency. Several epidemiologic studies link emergence and recurrence of this cancer to metabolic disorders. Glycosylation that modifies more than 80% of human proteins is one of the most widepread nutrient-sensitive post-translational modifications. Aberrant glycosylation participates in the development and progression of cancer. Thus, some of these glycan changes like carbohydrate antigen CA 19-9 (sialyl Lewis a, sLea) or those found on carcinoembryonic antigen (CEA) are already used as clinical biomarkers to detect and monitor CRC. The current review highlights emerging evidences accumulated mainly during the last decade that establish the role played by altered glycosylations in CRC drug resistance mechanisms that induce resistance to apoptosis and activation of signaling pathways, alter drug absorption and metabolism, and led to stemness acquisition. Knowledge in this field of investigation could aid to the development of better therapeutic approaches with new predictive biomarkers and targets tied in with adapted diet.

Authors : Very Ninon , Lefebvre Tony , El Yazidi-Belkoura Ikram ,

Related products :

Catalog number Product name Quantity
20-783-74648 MOUSE ANTI HUMAN BREAST CANCER RESISTANCE PROTEIN - Placenta-specific ATP-binding cassette transporter; Breast cancer resistance protein; Mitoxantrone resistance-associated protein; CD338 antigen; CDw 1 ml
EIAAB13066 EPDR1,Homo sapiens,Human,Mammalian ependymin-related protein 1,MERP1,MERP-1,UCC1,Upregulated in colorectal cancer gene 1 protein
ICTS-SER Cancer samples: Colorectal Cancer Serum-Adenocarcinoma Each
Tissues-123-COLORECTAL CANCER Human Tissues - COLORECTAL CANCER 1unit
orb61244 Erlotinib Erlotinib hydrochloride is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. For research use only. 100 mg
ABP-PVL-IRES10N Drug Resistance pCHAC_MCS_IRES_NeoR 1 ug
ABP-PVL-IRES10P Drug Resistance pCHAC_MCS_IRES_PuroR 1 ug
ABP-PVL-IRES10PL Drug Resistance pCHAC_MCS_IRES_PuroR 10 ug
ABP-PVL-IRES10NL Drug Resistance pCHAC_MCS_IRES_NeoR 10 ug
DR1H2_R2S Drug Resistance 1,DR1H2:2 SignArrays
DR1H2_R4S Drug Resistance 1,DR1H2:4 SignArrays
DR2H1_B12S Drug Resistance 2,DR2H1,12 SignArrays
Product-In-Demand Drug Resistance pLICO_EF1a_MCS_IRES_NeoR 1 ug
Product-In-Demand Drug Resistance pLICO_EF1a_MCS_IRES_NeoR 10 ug
DR2H1_B24S Drug Resistance 2,DR2H1,24 SignArrays
Product-In-Demand Drug Resistance pLICO_EF1a_MCS_IRES_PuroR 1 ug
DR2H1_B2S Drug Resistance 2,DR2H1,2 SignArrays
DR1H1_R8S Drug Resistance 1, DR1H1:8 SignArrays
DR2H2_R2S Drug Resistance 2,DR2H2:2 SignArrays
DR2H2_R4S Drug Resistance 2,DR2H2:4 SignArrays
DR1H1_F24S Drug Resistance 1,DR1H1:24 SignArrays
DR1H1_F12S Drug Resistance 1,DR1H1:12 SignArrays
DR2H1_B4S Drug Resistance 2,DR2H1,4 SignArrays
DR1H1_F2S Drug Resistance 1,DR1H1:2 SignArrays
DR1H1_F4S Drug Resistance 1,DR1H1:4 SignArrays


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur